Method for prevention of postoperative complications accompanying surgical management of patients with congenital malformations of external and middle ear
SUBSTANCE: invention relates to medicine, namely to otorhinolaryngology, and can be used for prevention of postoperative complications accompanying surgical management of patients with congenital malformations of external and middle ear. For this purpose, during the early postoperative period the ear is being cleaned, and the external acoustic meatus is being washed with an octenisept solution diluted in distilled water 1:5. Then, a session of endaural electrophoresis is performed with the Longidaza solution for 10–30 minutes. After the session of electrophoresis, a turunda impregnated with a mixture of preparations "Longidaza" and "Fermenkol" gel, 0.5 ml of each is being introduced into the external acoustic meatus. Turunda is being introduced 3 times a day for 10–15 days.
EFFECT: invention enables reducing the treating period and preventing commissure formation in the external acoustic meatus.
1 cl, 2 ex
SUBSTANCE: to determine density of otospongiosis focuses computer tomography of temporal bones with densitometry is carried out. Treatment duration is determined on the basis of obtained values of density. If density of otospongiosis focuses is less than 300 units HU, 4 courses of complex inactivating therapy are carried out. If density is 300-600 HU units -2 courses, if density is 600-900 units HU - 1 course. Duration of one course constitutes 3 months. During a year not more than two courses of therapy are carried out. Course of inactivating complex therapy includes intake of the following medications: bisphosphonates, sodium fluoride, calcium carbonate and vitamin D3. As bisphosphonates medication Bonviva is applied.
EFFECT: method makes it possible to increase efficiency of inactivating therapy in patients with different forms of active otosclerosis due to differential approach in selection of individual duration of carried out therapy.
SUBSTANCE: worker is exposed to therapeutic agents and physiotherapeutic procedures as a complex. The complex involves the combined administration of Preductal MB, Nicergolin and Neiromidin in the following doses: Preductal MB 35 mg 1 tablet 2 times a day per os for 14 days; Nicergolin 4 mg intramuscularly daily 2 times a day and Neiromidin 15 mg 1 time a day for 14 days. The physiotherapeutic procedures represent 10 daily 15-min procedures of aeroionotherapy and ultratonotherapy generated by an ear electrode in the course of 5 min for each ear.
EFFECT: invention enables reducing the length of treatment ensured by the functional improvement of the acoustic analyser tracts with delaying the disease progression, improving the hearing function, reducing sonitus, and increasing a whisper reception threshold.
1 tbl, 2 dwg
SUBSTANCE: what is presented is a method of treating exudative otitis media in children with the preparation Imunofan (synthetic hexapeptide with an immunoregulatory action). With underlying conventional treatment using antihistaminic, mucolytic and vasoconstrictive agents, politserisation, ear drum pneumassage, and laser therapy, the immunomodulator Imunofan is introduced intranasally into the children aged 3 to 7 years old according to the schedule: 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days, then 1 dose (50 mcg) into each nostril 1 time a day (at bedtime) daily for 14 days, and further again 1 dose (50 mcg) into each nostril 2 times a day daily for 7 days.
EFFECT: reducing the length of treatment, the probability of recurrent otitis, the number of complications and enabling a possibility to avoid surgical intervention.
1 dwg, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a pharmaceutical, ear, sterile, preservative-free composition in the form of a transparent aqueous solution, containing 0.01-0.025 % of fluocinilone acetonide optionally in a combination with 0.1-0.8% of ciprofloxacin or its pharmaceutically acceptable salt, a non-ionic surface-active substance, a tonicity-regulating agent and a viscosity-increasing agent.
EFFECT: composition is useful for the prevention and/or treatment of ear inflammation, optionally accompanied with a bacterial infection, and for the introduction of a single dose from a package.
15 cl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.
EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.
12 cl, 3 tbl, 21 ex
SUBSTANCE: group of inventions refers to medicine and concerns ear-drum or external auditory canal restoration. That is ensured by presented an agent containing a combination of gelatine sponge, basic fibroblast growth factor and fibrin glue, as well as using these ingredients for producing the agent. The method involves placing gelatine sponge containing a therapeutically effective amount of basic fibroblast growth factor within an ear-drum perforation or a defect of soft tissue of the external auditory canal and covering the sponge with fibrin glue.
EFFECT: inventions provide the effective defect closure and tissue restoration, including in the case where common methods are not applicable.
6 cl, 2 dwg, 3 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. A composition for treating an ear disease is introduced into the tympanic cavity, contains a polyoxyethylene-polyoxypropylene copolymer, an active substance specified in an immunomodulator, a vasopressin antagonist, an ion channel antagonist, a neurokinin receptor antagonist, a serotonin reuptake inhibitor, an NMDA-receptor antagonist, a prostaglandin analogue, a preparation having an effect on the central nervous system, a GABA receptor modulator, a cytotoxic agent, an antioxidant, a glutamate receptor modulator or a calcineurin inhibitor.
EFFECT: invention provides the prolonged release of the active substance into the internal ear for a period of time of at least 7 days.
14 cl, 3 dwg, 114 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: pharmaceutical composition for treating an infection containing mometasone furoate or a solvate thereof, Orbifloxacin, a fatty acid containing 3 to 18 carbon atoms and having a melting point of no more than about 60°; a method of treating an infection in an animal involving administration thereof, using the above composition for preparing a drug for treating the infection in the animal and a therapeutic kit for treating the infection comprising the above composition. The storage stability of the declared composition at room temperature is shown. The examples of the stable formulations of suspensions, e.g. for treating eye infection are provided.
EFFECT: preparing the pharmaceutical composition for treating the infection.
14 cl, 11 tbl, 3 ex
SUBSTANCE: intratympanic composition used for treating an ear disease contains: (a) an antimicrobial agent consisting of a number of particles; and (b) a polyoxyethylene and polyoxypropylene copolymer; the composition (i) is a liquid at room temperature; (ii) has a gelling point within the range of 19°C to 42°C; (iii) has a gel viscosity of 15000 sP to 1000000 sP; (iv) has an osmolarity less than 1000 mOsm/l; and the intratympanic composition release the antimicrobial agent in an ear for at least 5 days, and it is introduced at room temperature.
EFFECT: effective treatment of the ear diseases; the composition is non-toxic and has a non-irritating effect on the ear structures, provides the permanent prolonged release of the active agent with a reduced dose rate and reduces the risk of a potential tympanum damage.
13 cl, 9 tbl, 5 dwg, 30 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and deals with composition for application in treatment of ear diseases by intra-tympanum introduction into membrane of cochlea window or near membrane of cochlea window, which contains, acceptable for ear treatment thermoreversible water gel, which contains polymer of polyoxypropylene and polyoxyethylene and anti-apoptosis agent, slowed release of anti-apoptosis agent into cochlea taking place for, at least, 4 days.
EFFECT: invention ensures constant, slowed, prolonged release of active agent.
10 cl, 26 ex, 5 dwg
SUBSTANCE: invention refers to medicine, namely paediatrics and can be used for treating community-acquired pneumonia in children. That is ensured by prescribing an electrophoresis with an aqueous solution of the natural preparation Relikt-05 on the second day after temperature normalisation with a daily bipolar application of electrodes on the chest at current intensity 2 to 4-5 mA in children aged 3-7 years old and at 5 to 8 mA in children aged 7 and older with underlying drug therapy. The procedure length makes 10 to 15 minutes daily; the therapeutic course is 6-7 procedures.
EFFECT: method enables improving outcome of the integrated therapy in children suffering community-acquired pneumonia by faster resolution of infiltration centres in pulmonary tissue, increasing a neutrophil phagocytic rate and the content of active microelements, activating the endogenous antioxidant and antiradical protection with no complications.
3 ex, 2 tbl
SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for a stable osteosynthesis accompanying treating bone tissue injuries (endoprosthesis replacement, delayed union, false joints, chronic osteomyelitis). The stable osteosynthesis accompanying the bone tissue injuries involves using a bimetallic implant with various electrochemical potentials introduced into the bone tissue for inducing the bone tissue regeneration. The novel problem solution is using the bimetallic implant made of titanium and platinum with the total electrode potential difference 600 mV. The injuried bone tissue is exposed to an anode-polarised titanium component of the implant until observing a synthesis of the bone tissue continuity. The presented 'method for the stable osteosynthesis accompanying the bone tissue injuries' as compared to the known techniques enables combining all positive points of using metal structures complying with the current state of structures for the bone fracture osteosynthesis, and also provides polarisation of the components of the bimetallic implant, namely the anode polarisation of the titanium surface as a metal, directly contacting an internal environment of the bone that enables optimising the osteorepair process at the boundary of 'implant-bone' by the qualitative change of the regenerate and thereby providing more stable fixation of the metal structure.
EFFECT: method is widely used in medicine for optimising the osteorepair in the compromised osteogenesis (endoprosthesis replacement, delayed union, false joints, chronic osteomyelitis).
SUBSTANCE: group of inventions refers to medicine and comprises a device and method of treating sudorrhea and hyperhidrosis by the electric current exposure on a skin area to be treated. A device for treating sudorrhea by the electric current exposure on the skin area comprises a piece of clothing comprising a first electrode for contact with the above area, a second electrode for contact with the area or skin adjoining the area, and a power source electrically coupled to the above first and second electrodes.
EFFECT: group of inventions enables reducing sudorrhea by the electric current exposure on the skin area to be treated.
27 cl, 3 ex, 1 tbl, 6 dwg
SUBSTANCE: invention refers to medicine, namely to neurosurgery, resuscitation and neurology, and may be used for treating the permanent unconscious vegetative state. That is ensured by intratympanic streptomycin treatment with underlying common drug therapy of the state. The completion of the above is followed by the electric transcranial exposure on the brain. For the intratympanic treatment, streptomycin 1 g is dissolved in physiologic saline 1 ml. The preparation is introduced once a day from one side, and on the other day from the opposite side. The therapeutic course is 5-10 days. The electric transcranial exposure is presented by transcranial DC micropolarisation of intensity 200-400 mcA for 30-40 minutes daily for 16-24 days. The exposure is performed through 3-4 electrodes places on the areas of temporo-caudal projections and posterior associated cortical areas from both sides. For the first 6 days, such exposure covers the temporo-caudal projections, while on the other days the posterior associated cortical area projections are exposed. If required, the above therapeutic courses are repeated not earlier than in 3 months until the clear consciousness is reached.
EFFECT: method provides an immediate and convincing clinical effect without brain invasiveness, an ability to recover the clear consciousness in these patients, as well as a significant reduction of the pathologically increased muscle tone and as a result, achieved satisfactory level of the patient's self-service.
SUBSTANCE: invention refers to medicine, more specifically to physiotherapy, otorhinolaryngology, audiology, rehabilitation medicine, and may be used for the physiotherapeutic body exposure in the diseases developed in cerebral and cervical human tissues and organs, such as perceptive hearing loss, siagonantritis, eustachitis, temporomandibular dysfunctional pain syndrome, odontogenous or rhinogenous trifacial neuralgia, Bell's palsy etc. For this purpose, a concha of auricle is exposed to electric current by introducing an electrode into an ear to contact a cavity and cup of concha tightly. Besides, the above are exposed to electric current through an electrode placed into a nasal passage. The electrodes are wrapped in a wet tissue made of a non-woven material with surface density 160-180 g/m2 containing a polymer layer of sodium alginate containing a drug preparation or a mixture thereof. The exposure is generated by direct electric current with its intensity to be gradually increased from 1 to 5 mA. The procedures are sequential at first from one side, and then from the other side. The exposure time makes 10-15 minutes from each side. The therapeutic course is 8-12 daily procedures.
EFFECT: appropriate prescription of the drug preparations enables the method providing the evident analgesic and anti-inflammatory action, activation of the tissue immune processes, improved innervation within the exposure region, recovered locomotor function of the temporomandibular joint and masticatory muscles, higher contractive activity of the muscles of expression, reduced development of any negative responses and complications ensured by the combined action of direct electric current and prolonged action of the pharmacological preparations in the presented tissues.
SUBSTANCE: invention refers to a device and method of treating bacterial diseases. The device comprises a trocar, a perforator, a pusher, a silver electrode, a temporary electrode, a needle made of a biocompatible material having a negative electric potential to silver, one or more second electrodes made of the same material as the needle, an external DC voltage, and a conductivity metre. The method using the device involves the stages of drilling a hole in an infected bone or within an infected area, implanting the small silver electrode therein, placing the temporary electrode in the hole above the silver electrode in close contact therewith, establishing an electrical connection of the temporary electrode to a first clamp of the conductivity metre, establishing an electrical connection of the needle to a second clamp of the conductivity metre, touching the skin surface with the needle in a point close to the hole and measuring the path conductivity from the silver electrode to the needle, restarting a touch pitch in various skin locations as long as the path having the highest electrical conductivity is found, and marking the corresponding needle location, disconnecting the conductivity metre from the temporary electrode and removing the conductivity metre and the needle, introducing the second electrode subcutaneously in the marked location, establishing an electrical connection of one clamp of the DC voltage to the temporary electrode, and its second clamp - to the second electrode, passing the current of less than 0.5 mA for 5-120 s between the silver electrode and the second electrode, disconnecting the second clamp of the DC voltage from the second electrode, removing the temporary electrode and the DC voltage.
EFFECT: using the invention provides a prolonged antibacterial effect which has a preventive effect and after completion of the therapeutic course of infection.
18 cl, 13 dwg
SUBSTANCE: invention relates to field of medicine, namely to dentistry, and can be applied for physiotherapeutic treatment of patients with neuropathy of lower alveolar and mental nerves. Device for electrophoresis contains case and active and passive electrodes, connected with cables, connected to apparatus for physiotherapy. Case is made in form of hollow cone with cylindrical tip on one end, equipped with rubber nozzle. Active electrode is placed in body and is made in form of hydrophilic padding, soaked with medication, with possibility of 2-3 mm projection of hydrophilic padding beyond ranges of rubber nozzle to provide close contact with zone of influence, and cotton cylinder, soaked with physiological solution, placed close to hydrophilic padding and connected with cable clamp, which projects outside through opening in lid, installed on the other case end. The remaining part of case is tightly filled with cotton. Passive electrode is made in form of plate with size 1×2 cm.
EFFECT: prevention of current escape, creation of high concentration of electric field of fluctuating current in zone of mental opening and ensuring acceleration of medical substance ions travel into area of mental opening and mandibular canal by creation of tight contact of device padding with oral cavity mucosa and ensuring its exact placement in area of mental opening.
SUBSTANCE: invention refers to medicine, specifically to physiotherapy, surgery, and traumatology. The method involves placing a pair of oppositely charged electrodes on the patient's body If observing an arterial bleeding, the electrodes are placed above a damage area in a projection of the artery causing bleeding in the specified area. The positive and negative electrodes are placed on the right and left from the blood flow direction in this artery respectively. If observing a venous bleeding, the electrodes are placed below the damage area in a projection of the vain causing bleeding in the specified area. The positive and negative electrodes are placed on the right and left from the blood flow direction in this vein respectively. A mixed bleeding requires the positive electrode to be placed above the damage area in a projection of the artery causing bleeding in the specified area, and a negative electrode to be placed below the damage area in a projection of the vein causing bleeding in the specified area.
EFFECT: method simplifies a bleeding reduction procedure.
SUBSTANCE: invention refers to medicine and aims at treating amnestic syndrome. A local anaesthesia is applied by infiltration of the tissues surrounding the external auditory canal with 0.5% novocaine along an anteromedial surface of the mastoid process bypassing the eardrum directly into the ear. The therapeutic effect is implemented by administering 1 g of streptomycin dissolved in 1 ml of physiological saline, intratympanic from one or both sides once a day every 2-3 days, with the manipulations performed 2 to 5 times per a course during 10-20 days. The transcranial exposure is generated by direct electric current at the intensity of 200-600 mA in the mid-temporal area of the head for 20-40 minutes daily for 8-10 days, repeated 2-3 times every 1-2 months. The electric exposure is generated by applying lead electrodes with each electrode having an area of 400-600 mm.
EFFECT: method enables improving associative cortex activity and improving the clinical effectiveness.
3 cl, 2 ex
SUBSTANCE: invention refers to medicine, namely to physiotherapy, gastroenterology. The method involves dietary therapy No. 5, general pine baths, magnetic laser therapy, intake of mineral water with underlying sparing training regimen followed by transverse galvanisation of the epigastrial area. The transverse galvanisation immediately follows the intake of mineral water between 10 to 11 o'clock. Additionally, the right hypochondrium and sternum are exposed to EHF radiation generated by a broadband noise transducer with a frequency of 40-63 GHz, for 10 minutes per each area, every day; the therapeutic course is 10-12 procedures.
EFFECT: method enables higher clinical effectiveness ensured by using a chronobiological approach to treating the patients for the purpose of relieving the functional disorders of the bile system with underlying increased adaptive capacities of the body.
2 ex, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a composition containing a mixture of at least one proteolytic enzyme, such as subtilisin or nattokinase, and at least one lipolytic enzyme specified in a group containing lipase Cal A or Cal B of Candida anthartica, Geotrichum candidum, Candida rugosa or a mixture of these lipases to be used preventing triglyceride synthesis by splitting 2-monoacylglyceryl in the intestine, and to a combined product of the above product of the above enzymes for the above application. The technical effect consists in preventing triglyceride formation in the body under the action of the declared combination of subtilisin and lipases with the reduced blood lipoproteins maintained 8 hours after the administration thereof.
EFFECT: inventions can be used as a therapeutic agent, a cosmetic agent, a medication, a food composition, a food supplement or a nutriceutical for preventing or treating obesity, atherosclerosis, for preventing or reducing overweight.
23 cl, 2 dwg